1月21日，江苏爱舍伦医疗科技集团股份有限公司在北京证券交易所上市，成为2026年江苏省及苏州市 首家新增A股上市公司。另外，数据统计显示，2025年A股共计116家企业首发上市，苏州企业数量多达 12家，相当于每10家新上市公司中就有1家来自苏州，超过一线城市，位居各城市第一位。 苏州之后，同处苏南的无锡经济总量长期位居普通地级市第二位。数据显示，2025年全年全市实现地区 生产总值16773.94亿元，按不变价格计算，同比增长5.1%。从县域经济来看，当前中国县域GDP前五强 中，有4个位于苏南地区，即"苏南四小龙"（昆山、江阴、张家港和常熟），其中昆山、张家港和常熟 来自苏州，江阴来自无锡。 2025年GDP过万亿的普通地级市达到10个，比上一年增加1个。温州市统计局的数据显示，根据地区生 产总值统一核算结果，2025年，全市地区生产总值（GDP）历史性迈上万亿台阶，达10213.9亿元，按 不变价格计算，比上年增长6.1%，分别高于全国、全省1.1和0.6个百分点。 其中，2025年，温州全市规上工业增加值比上年增长10.3%，持续领跑全省。分行业看，33个行业大类 中，28个行业增加值实现正增长，增 ...

203+ 410+ 9911+ 007+ L T I t t 来源：梧桐树下v 继2025年IPO募资额问鼎全球榜首之后，港股市场在2026年延续了这份灼热势头——截至1月28日，已有13家企业在港交所敲锣。在这场资本浪潮中，中资 券商已悄然蜕变，凭借对中国资产的深刻理解、跨境资源整合能力，已成为连接内地优质企业与全球资本的核心枢纽，源源不断地为港股市场的持续繁荣注 入新动能。 2025年，港股市场迎来强势复苏，全年共有119只新股成功上市，募资总额高达约2858亿港元，上市数量和募资规模双双攀升。这也是港交所时隔4年IPO募 资规模再度突破2000亿港元整数关口，成功夺回全球IPO募资额榜首。 在这场IPO盛宴中，各大中介机构通力护航，其中中资券商扮演的角色日益关键，Wind数据显示，2025 年港股按承销金额排名的前十大股权承销商中，中 资券商占据六席，合计市场份额56.15%，并形成以中金国际、中信证券（香港）为核心，华泰金控、广发证券（香港）、中信建投国际等紧随其后的竞争 梯队。 从券商2025年三季报可见，上述领先券商均实现营收与利润的显著增长，其中中金公司营收与归母净利润同比分别增长54.4%与1 ...

Core Insights - During the "14th Five-Year Plan" period, Jiangsu is advancing the reform of the healthcare service system through digitalization and intelligence, with a focus on the interconnectivity and sharing of medical imaging data [1] Group 1: Medical Imaging Data Platform - Jiangsu has established a provincial-level medical imaging data operation service platform that breaks down data barriers between public medical institutions, allowing patients to access imaging data and reports across different hospitals [1] - This platform is expected to save patients nearly 2 billion yuan annually by avoiding redundant examinations, thereby laying a digital foundation for the distribution of quality medical resources [1] Group 2: Grassroots Medical Alliance - The company is advocating for the establishment of a tightly-knit grassroots medical alliance, supported by a digital platform, to empower local healthcare services and ensure that citizens have access to quality medical care nearby [2] - In Nanjing's Gulou District, a collaboration has been initiated to create a regional imaging digital platform connecting 11 community health service centers, enhancing centralized management and data aggregation of examinations [2] Group 3: Patient Experience and Future Plans - Patients in Gulou District can now view high-definition images and reports by scanning a QR code on their examination report, with the platform having uploaded nearly 10,000 imaging examinations and conducted over 100 remote consultations [3] - The company emphasizes the importance of practical research to ensure that proposals and suggestions are precise and actionable, aiming to contribute to the high-quality development of health services in Jiangsu [3]

Core Viewpoint - Multiple hospitals in the city have recently launched various AI tools aimed at enhancing patient convenience during medical visits, including AI assistants for navigation, real-time consultations, and traditional Chinese medicine diagnostics [1][9]. Group 1: AI Medical Assistants - The "Health Smart Person" service at the Japan-China Friendship Hospital provides comprehensive assistance, including route guidance, appointment reminders, and medication consultations [3][4]. - The AI assistant proactively sends reminders based on the patient's progress through key stages such as registration, waiting, payment, examination, and medication collection [4]. Group 2: AI Doctors - An AI doctor developed by Ditan Hospital can assess symptoms and provide personalized advice for common illnesses like flu and respiratory infections, with input from nearly 60 infection specialists [7][8]. - The AI doctor is designed to assist in preliminary risk assessments before medical visits and offer medication explanations and recovery guidance afterward [8]. Group 3: Traditional Chinese Medicine Integration - Beijing Friendship Hospital is researching the integration of AI with traditional Chinese medicine, specifically using tongue diagnosis to assess liver disease risks [9][10]. - The goal is to enable patients to use a mobile app to take pictures of their tongues and receive quick assessments of liver fibrosis risk, with a standardized tool for image capture expected to be developed by the end of the year [10][11].

Core Viewpoint - The company, Yidu Tech (02158), is actively repurchasing shares, signaling confidence in its long-term value while also making significant strides in business collaborations within the healthcare sector [1] Group 1: Share Repurchase - On January 30, Yidu Tech repurchased approximately 786,000 shares at around HKD 5.8 per share, costing over HKD 4.5 million [1] - The total amount spent on share repurchases over the past five days exceeds HKD 9.5 million, indicating a strong commitment to enhancing shareholder value [1] Group 2: Business Collaborations - Yidu Tech has established a strategic partnership with the Nanshan District People's Hospital in Shenzhen, launching the first domestic "AI + Health Management" innovative system that covers "full-time, full-domain, full-population, and full-cycle" [1] - This initiative aims to create a closed-loop AI medical ecosystem from research and development to application and transformation, marking a significant step in the implementation of smart healthcare solutions [1] Group 3: Market Developments - The company has reported that the number of participants in the 2026 "Beijing Universal Health Insurance" program has surpassed 4.5 million, showcasing its operational capabilities [1] - Additionally, Yidu Tech has collaborated with the First Affiliated Hospital of Chongqing Medical University to launch an "AI Assistant for General Medicine," further expanding its influence in the healthcare sector [1] - Market observers note that the combination of continuous share repurchases and multiple business collaborations highlights the company's dual strategy of "technological breakthroughs + scenario implementation," deepening its impact in the fields of medical intelligence and universal health [1]

Core Insights - Alibaba Health's AI product "Hydrogen Ion" has partnered with the Chinese Medical Association to integrate top-tier medical resources into its platform, enhancing the accessibility and usability of authoritative medical knowledge for clinicians and researchers [1][2] - The collaboration aims to convert medical academic resources into a structured knowledge system that supports precise sourcing and retrieval, addressing challenges faced by doctors in keeping up with rapid updates and finding reliable information [1] Group 1 - The partnership will enable doctors to ask natural language questions and receive immediate answers based on the latest evidence-based guidelines, along with precise citations for reference [1] - Researchers will benefit from intelligent cross-journal and cross-disciplinary searches, improving knowledge association and retrieval capabilities [1] - The Chinese Medical Association's clinical guidelines and expert consensus are considered industry "gold standards," providing invaluable guidance to frontline clinical and research doctors [1] Group 2 - The Director of the New Media Department of the Chinese Medical Association expressed optimism about the collaboration, highlighting the new evidence-based information paradigm that Hydrogen Ion will provide to doctors [2] - Hydrogen Ion focuses on addressing the real needs of doctors in clinical and research settings, aiming to enhance its core functionalities in evidence support, intelligent retrieval, and literature review [2] - The goal is to ensure that doctors receive accurate answers backed by evidence in their clinical and research endeavors [2]

Core Insights - Huawei is set to launch its "Smart Medical Zone" as part of its industry AI "Dream Factory" plan on February 1, 2026, at the Medical AI Collaborative Innovation Forum in Shanghai [1][3] - The initiative aims to address the shortage of pathology doctors in China, where there are currently fewer than 20,000 registered pathologists, with a shortfall of 140,000, and 80% of these professionals are concentrated in major cities [3] Group 1 - The Smart Medical Zone will integrate top medical resources with AI technology to tackle structural challenges in pathology diagnosis, such as talent shortages and uneven resource distribution [1][3] - Since 2021, Huawei has partnered with Shanghai Ruijin Hospital to develop the pathology AI field, establishing China's first digital smart pathology department and planning to release a clinical-level pathology model, RuiPath, covering over 90% of common cancer types by 2025 [3] - The launch of the Smart Medical Zone signifies Huawei's commitment to consolidating ecosystem forces and positioning itself at the forefront of the national strategy for "AI + Healthcare," aiming to break down barriers in medical resources and scale AI capabilities to grassroots medical institutions [3]

Core Viewpoint - The announcement from Keda Xunfei regarding its 2025 profit forecast indicates a projected net profit growth of 40% to 70%, highlighting the resilience of its core business and signaling that AI-driven vertical commercialization has entered a harvest phase [1] Group 1: Company Performance - Keda Xunfei's growth is attributed to its "platform + scenario" strategy, with the medical sector being a significant contributor to this growth [2] - The medical business has achieved substantial market penetration, with over 77,000 grassroots medical institutions deploying its core product, the Intelligent Medical Assistant [2] - The download count for the personal health assistant app "Xunfei Xiaoyi" has surpassed 26 million, indicating strong user engagement and service capability [2] Group 2: Technological Advancements - The "Xunfei Spark" large model is the only mainstream model in China trained on domestically produced computing power, maintaining competitive technical indicators globally [3] - The medical deep reasoning model, based on the Spark model, has outperformed leading models like GPT-5 in various medical applications, achieving capabilities equivalent to senior hospital physicians [3] - In 2025, Keda Xunfei's large model projects won contracts worth 2.316 billion yuan, surpassing the combined total of the second to sixth competitors in the industry [3] Group 3: Market Dynamics - The global AI medical market is projected to exceed $100 billion by 2025, with a compound annual growth rate of over 25%, driven by the demand for AI applications in grassroots healthcare [5] - Keda Xunfei is positioned to leverage its domestic experience to address global healthcare challenges, particularly in emerging markets [6] - The company is actively exporting its successful grassroots medical AI solutions, aiming to capture growth opportunities in the global market [6] Group 4: Investment Implications - The profit growth forecast from Keda Xunfei signals to the capital market that medical AI has transitioned from concept to scalable profitability, with the company positioned as an industry leader [7] - Unlike many US competitors that remain unprofitable, Keda Xunfei has achieved profitability and continues to optimize its business model, suggesting significant valuation upside [7] - The sustainable technological barriers established by Keda Xunfei, through its comprehensive ecosystem of large models, data, and application scenarios, provide a strong foundation for long-term valuation support [7] Conclusion - Keda Xunfei's 2025 profit forecast reflects confidence in the commercialization of AI, indicating not only a spillover effect on the parent company's performance but also the independent commercial value of its medical technology [8] - The company is carving out a unique path in AI medical commercialization, deeply embedding itself in the transformation of China's healthcare system [8]

Core Viewpoint - The announcement from Keda Xunfei (002230) regarding its 2025 annual performance forecast indicates a projected net profit growth of 40% to 70% year-on-year, highlighting the resilience of its core business and signaling that AI-driven vertical scene commercialization has entered a harvest phase [1] Group 1: Company Performance - Keda Xunfei's growth is attributed to its "platform + scene" strategy, with the medical sector being a significant contributor to this growth [1] - The medical segment has achieved substantial market penetration, with core product "Smart Medical Assistant" deployed in over 77,000 grassroots medical institutions nationwide [2] - The company reported that its medical AI projects won contracts worth 2.316 billion yuan in 2025, surpassing the combined total of the second to sixth competitors in the industry [3] Group 2: Technological Advancements - The "Xunfei Spark" large model is the only mainstream model in China trained on domestically produced computing power, maintaining competitive technical indicators globally [3] - The medical deep reasoning model, based on the Spark model, has outperformed competitors like GPT-5 and DeepSeek V3.2-Exp in various medical applications [3] - The company has established a complete ecosystem combining large models, data, and application scenarios, creating a competitive advantage that is difficult for peers to replicate [7] Group 3: Market Trends - The global AI medical market is projected to exceed $100 billion by 2025, with a compound annual growth rate of over 25%, particularly in grassroots medical AI applications [5] - Keda Xunfei is positioned to provide replicable solutions for global healthcare challenges, leveraging its experience in the Chinese market [6] - The company is seen as a leader in the AI medical sector, with its valuation expected to rise as it continues to optimize its business model and maintain its technological barriers [7] Group 4: Future Outlook - The performance forecast serves as a confidence vote for the commercialization of AI, indicating that Keda Xunfei's medical technology is not only a spillover effect from its parent company but also a signal of its independent commercial value [8] - The company is on a unique path of AI medical commercialization, deeply embedded in the transformation of the Chinese healthcare system [8]

Core Insights - Data security and domestic substitution have become the core benchmarks for government and enterprise procurement, particularly in the medical technology sector, where competition has shifted from pure technology comparison to a comprehensive contest of full-stack capabilities and commercial implementation [1] Group 1: Company Performance - In 2025, iFlytek secured 210 large model bidding projects with a total bid amount of 2.316 billion yuan, ranking first among the top six general large model vendors [1] - iFlytek's medical sector leads in both the number and amount of bids, becoming a core growth driver for the company in the large model arena [1][3] - The company anticipates a net profit growth of 40% to 70% year-on-year for 2025, with non-recurring net profit expected to grow by 30% to 60% [2] Group 2: Market Position and Competitive Advantage - iFlytek's medical model orders have seen explosive growth, showcasing significant growth potential and establishing a unique full-stack capability that differentiates it from competitors like Baidu and Alibaba Health [3][4] - The "iFlytek Spark" model is the only mainstream large model in China trained on fully domestic computing power, achieving global leading performance in various sectors including education and healthcare [4] - The company has established a strong foothold in the CDSS market for grassroots medical institutions, achieving a market share of 61.5% in 2023 [10] Group 3: Policy Alignment and Market Demand - iFlytek's technology aligns well with national policies aimed at improving grassroots medical service capabilities and optimizing healthcare resource allocation, making its medical large model a key tool in government procurement [7][8] - The company's intelligent medical assistant has covered over 77,000 grassroots institutions across 31 provinces, providing 1.1 billion diagnostic suggestions, thus enhancing the quality of care in line with national healthcare policies [8] Group 4: Long-term Growth Potential - iFlytek's unique position as the "first stock of medical large models" provides it with significant capital market recognition and advantages in resource integration [9] - The GBC (Global Business Collaboration) commercial loop enhances its long-term growth value by effectively linking technology implementation with commercial monetization [10][11] - The company reported a revenue of 299 million yuan in the first half of 2025, a year-on-year increase of 30.26%, with a significant reduction in net losses by 42.86% [11]